Our original hypothesis was that glycolipids can be of value in improving the pathological classification of human gliomas. During the current funding period we obtained considerable supporting information for this hypothesis. Most significantly, we found that a decrease in the proportion of gangliosides of the 1b pathway and the presence of 6'-LM1 correlate with shorter survival times. The group of tumors on which these observations were made is the training set. Here we propose; (1) To test these findings independently in a validation set that we are establishing, and then (2) To evaluate their practical usefulness in a large group-wide study that will focus on creating a panel of markers to improve upon the classification of human gliomas in a clinically beneficial way. In addition, we will examine several other selected glycolipids and their correlation with diagnosis and/or survival using the training set for which glycolipids and consensus diagnoses of the neuropathology panel are available. Those found to correlate with diagnosis and/or survival in the training set will then be studied further using both the validation set and the group-wide set of gliomas. The goal of these studies is to find a pattern of glycolipids that can provide prognostic information beyond that of currently available methods. Such a panel of diagnostic glycolipid markers will provide the basis for improvements in the pathological classification of human gliomas. We will also continue to cooperate with other members of the Glioma Marker network to advance the goals of the RFA by participating in the Coordinating Committee (Yates, Pearl, Mam-ak), neuropathological review sessions (Yates), statistical collaboration with other institutions (Pearl), and maintenance of a group database (Pearl and Mamrak).

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01CA050910-08
Application #
2007796
Study Section
Special Emphasis Panel (SRC (90))
Project Start
1989-09-01
Project End
1998-11-30
Budget Start
1996-12-01
Budget End
1997-11-30
Support Year
8
Fiscal Year
1997
Total Cost
Indirect Cost
Name
Ohio State University
Department
Pathology
Type
Schools of Medicine
DUNS #
098987217
City
Columbus
State
OH
Country
United States
Zip Code
43210
Popko, Brian; Pearl, Dennis K; Walker, Diane M et al. (2002) Molecular markers that identify human astrocytomas and oligodendrogliomas. J Neuropathol Exp Neurol 61:329-38
Burger, P C; Pearl, D K; Aldape, K et al. (2001) Small cell architecture--a histological equivalent of EGFR amplification in glioblastoma multiforme? J Neuropathol Exp Neurol 60:1099-104
El-Abbadi, M; Seyfried, T N; Yates, A J et al. (2001) Ganglioside composition and histology of a spontaneous metastatic brain tumour in the VM mouse. Br J Cancer 85:285-92
Smith, J S; Perry, A; Borell, T J et al. (2000) Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J Clin Oncol 18:636-45
Smith, J S; Alderete, B; Minn, Y et al. (1999) Localization of common deletion regions on 1p and 19q in human gliomas and their association with histological subtype. Oncogene 18:4144-52
Yates, A J; Franklin, T K; McKinney, P et al. (1999) Gangliosides and neutral glycolipids in ependymal, neuronal and primitive neuroectodermal tumors. J Mol Neurosci 12:111-21
Yates, A J; Franklin, T K; Scheithauer, B W et al. (1999) Sex- and age-related differences in ceramide dihexosides of primary human brain tumors. Lipids 34:1-4
Yates, A J; Comas, T; Scheithauer, B W et al. (1999) Glycolipid markers of astrocytomas and oligodendrogliomas. J Neuropathol Exp Neurol 58:1250-62
Comas, T C; Tai, T; Kimmel, D et al. (1999) Immunohistochemical staining for ganglioside GD1b as a diagnostic and prognostic marker for primary human brain tumors. Neuro Oncol 1:261-7
McGee, S W; Saqr, H E; Hynds, D L et al. (1998) Expression of recombinant beta-platelet-derived growth-factor receptor in Sf9 insect cells as a model to study receptor-ganglioside interactions. Ann N Y Acad Sci 845:417

Showing the most recent 10 out of 17 publications